Effectiveness of PRP, Conditioned Medium UC-MSCs Secretome and Hyaluronic Acid for the Treatment of Knee Osteoarthritis

• Status: Active, not recruiting
• Trial end date: 2023-05-31
• Target enrollment: 0
• Participant gender: All

Summary

The clinical trial will be carried out at the Dr. Moh. Hoesin Central Hospital, Palembang and planned from October 2022 to March 2023.

This study aims to compare the efficacy of Platelet Rich Plasma, Conditioned Medium From Umbilical Cord Mesenchymal Stem Cell (MSC) Culture Secretome and hyaluronic acid for the Treatment of Knee Osteoarthritis

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universitas Sriwijaya
• Collaborator: Dr. Mohammad Hoesin Central General Hospital
• Treatments: Hyaluronic Acid

Criteria

Inclusion Criteria:

• Patients aged 30-60 years

• Suffering from grade 2 and 3 osteoarthritis (OA) was identified by two observers who differed accordingly the Kellgren and Lawrence research scale

• Patient with knee pain that had been continuing for at least 12 months with no relief using anti-inflammatory medications and that deteriorated with weight-bearing

• Patients can understand the nature of the study and written informed consent is given to patients

Exclusion Criteria:

• Age > 60 years

• Acute Knee Osteoarthritis Effusions

• Patients are not willing to obey the study protocol

• There are signs of infection local or general infection or positive serology for HIV, hepatitis and syphilis

• There is a congenital disease that causes significant deformity of the knee can interfere with cell applications and interpret results

• Articular injection of the knee by any drug during the previous 3 months

• Participate in any clinical trial or treatment 30 days before the study

• Other conditions may, according to medical criteria, not support participation in this research (The recent history of knee trauma, Autoimmune rheumatic diseases, Uncontrolled systemic diseases such as diabetes or hypertension, patient with Immunosuppressive or anticoagulant treatment and cancer)